23andme stock

A concise wiki-style guide to 23andme stock: what the equity represents, its public‑market history (SPAC listing), subsequent trading under OTC tickers, major corporate events that affected shares,...

2024-07-04 11:44:00

By Crypto Linguist

Article rating

4.4

102 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

23andme stock refers to the publicly traded equity of 23andMe Holding Co., a U.S. consumer genetics and therapeutics company. This article explains what 23andme stock is, summarizes the company’s business lines, traces public‑market and ticker history, and outlines the practical implications for holders and researchers following the name on exchanges and quotation services.

Company overview

23andMe operates two primary lines: Consumer & Research Services (direct‑to‑consumer genetic testing, subscription services and research partnerships) and a therapeutics research arm that develops drug targets using aggregated genetic data. The company was founded with a consumer DNA testing focus and expanded into research collaborations and therapeutics development over time.

Public listing and ticker history

23andme stock first entered public markets after a SPAC merger in 2021. As of June 3, 2021, according to company filings and contemporaneous finance coverage, 23andMe completed its SPAC combination and began public trading under the ticker ME on Nasdaq. Over time, corporate events and regulatory actions changed its registration and listing status; in later periods the company’s equity and remnants of its capital structure were quoted on OTC venues under identifiers such as MEHCQ.

Major corporate events affecting the stock

Key corporate developments that materially affected 23andme stock included sustained operating losses, strategic shifts between consumer testing and therapeutics investment, and formal restructuring steps. These events drove volatility in the equity, influenced liquidity for retail holders, and prompted wide media coverage in financial outlets.

Delisting, deregistration and post‑delisting status

After the company experienced financial and regulatory pressures, 23andme stock was removed from major exchange listings and its public reporting status changed. As of June 1, 2024, according to major finance quotation services, the company (or portions of its capital structure) was quoted on over‑the‑counter venues rather than Nasdaq. Delisting and deregistration reduce SEC reporting frequency and typically shift trading to lower‑liquidity OTC markets.

Trading information and market data

Price and volume history for 23andme stock and related OTC tickers can be found on mainstream finance pages, broker quote screens, and OTC market data pages. Reported quotes on OTC listings are often thin and can differ across data vendors; market capitalization and daily volume fell substantially relative to peak public valuations during restructuring periods.

Financial performance

23andme stock performance was heavily influenced by multi‑year net losses, negative EPS, and cash‑burn dynamics tied to R&D and customer acquisition. Those financial trends were a major factor in restructuring decisions and in changes to listing status.

Ownership, creditors and major stakeholders

Institutional and retail investors previously held 23andme stock through the public listing; during restructuring, creditor claims and any asset‑sale outcomes had priority over equity claims. Equity holders faced uncertainty about recovery amounts and timing through any court‑supervised processes.

Regulatory, legal and data‑privacy issues

Investor sentiment around 23andme stock was also shaped by regulatory and privacy considerations: handling of customer genetic data, disclosure obligations, and court or regulatory scrutiny can materially affect both operational options and equity value.

Market reception and analyst coverage

During periods of restructuring, mainstream media and specialized investor forums provided frequent coverage of 23andme stock. Analyst coverage tightened as uncertainty rose, and retail discussion appeared on social platforms and broker comment pages.

Investment considerations and risks

Prospective or current holders should note principal risks tied to 23andme stock: potential delisting, low liquidity on OTC markets, priority of creditor claims in restructuring, regulatory and privacy risk, and the possibility of partial or total loss of equity value. This article is informational and not investment advice.

How to follow or research the stock

To follow 23andme stock, consult brokerage quote pages, finance sites that track OTC tickers, and official SEC filings when available. For trading or market access, consider using Bitget as your exchange choice and Bitget Wallet for Web3 custody and related features. Monitor primary sources such as company filings and bankruptcy‑court documents for authoritative updates.

References and sources

As of June 3, 2021, according to company filings and finance coverage (SPAC merger completion)
As of June 1, 2024, according to major finance quotation services (OTC quotations such as MEHCQ)
Reporting and market summaries from CNBC/NBC, Yahoo Finance, Business Insider, Robinhood investor pages, StockTwits, Barchart and Public.com (dates and specific articles available via those outlets).

Further reading: check company reports, SEC filings and court dockets for the most current, primary documentation about 23andme stock and any restructuring outcomes.

Note: This article summarizes public reporting and does not provide investment advice. For platform access or trading features, learn more about Bitget and Bitget Wallet.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.